A pilot study of the immune response to whole inactivated avian influenza H7N1 virus vaccine in mice by Hovden, Arnt-Ove et al.
A pilot study of the immune response to whole
inactivated avian inﬂuenza H7N1 virus vaccine in mice
Arnt-Ove Hovden
a,b, Karl A. Brokstad
b,c, Diane Major
d, John Wood
d, Lars R. Haaheim
a,
Rebecca J. Cox
a
aThe Inﬂuenza Centre, The Gade Institute, University of Bergen, Bergen, UK.
bBroegelmann Research Laboratory, The Gade Institute, University of
Bergen, Bergen, Norway.
cDepartment of Otolaryngology⁄Head and Neck Surgery, Haukeland University Hospital, Bergen, Norway.
dNational
Institute for Biological Standards and Control (NIBSC), South Mimms, Herts, UK.
Correspondence: Rebecca Jane Cox, The Inﬂuenza Centre, The Gade Institute, University of Bergen, Armauer Hansen Building, Haukelandsveien 28,
N-5021 Bergen, Norway.
E-mail: rebecca.cox@gades.uib.no
Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
Accepted 6 January 2009. Published Online 19 February 2009.
Background Highly pathogenic avian inﬂuenza (HPAI) outbreaks
in domestic poultry bring humans into close contact with new
inﬂuenza subtypes and represent a threat to human health. In
1999, an HPAI outbreak of H7N1 virus occurred in domestic
poultry in Italy, and a wild-type virus isolate from this outbreak
was chosen as a pandemic vaccine candidate.
Objectives We conducted a pilot study to investigate the kinetics
of the humoral immune response induced after immunisation
with an egg grown whole inactivated H7N1 virus vaccine in
BALB⁄c mice.
Methods Mice were vaccinated with one or two doses of H7N1
vaccine (15 lg total protein) to investigate the inﬂuenza speciﬁc
antibody secreting cell (IS-ASC) and serum antibody responses.
Results After the ﬁrst dose of vaccine, only IgM IS-ASC were
detected in the spleen and bone marrow, whereas IgG, IgA and
IgM IS-ASC were found after the second dose. Low antibody
titres were detected after the ﬁrst immunisation, whilst the second
dose of vaccine signiﬁcantly boosted the HI (range 128–512),
neutralising and IgG antibody titres. The IgG subclass response
was dominated by IgG2a indicating a dominant Th1 response
after the ﬁrst vaccination, whereas a more mixed Th1⁄Th2 proﬁle
was observed after the second dose.
Conclusions This pilot study shows the value of using a number
of immunological methods to evaluate the quality of the immune
response to potential pandemic candidate vaccines.
Keywords Inﬂuenza H7N1, whole virus vaccine, mice.
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Introduction
Aquatic birds are the natural reservoir for all known inﬂu-
enza A subtypes, and constitute a risk factor for the intro-
duction of these new subtypes into man. Recently, the
urgency for development of pandemic inﬂuenza vaccines
has been highlighted by a number of avian inﬂuenza A
subtypes (H5, H7 and H9) crossing the species barrier and
infecting humans resulting in illness and death (reviewed
in Ref.1). Two of these inﬂuenza A subtypes (H5 and H7)
exist as low pathogenic (LPAI) and highly pathogenic avian
inﬂuenza (HPAI) viruses. Highly pathogenic avian inﬂu-
enza outbreaks represent a potential risk to human health,
as demonstrated by 403 human cases of H5N1 that have
resulted in 254 deaths mainly in South-East Asia up to Jan-
uary 2009.
2 However, in Europe and North America most
HPAI outbreaks are caused by the H7 subtype and this has
resulted in conjunctivitis, illness and one known death.
3–6
Parenterally administered inactivated inﬂuenza vaccines
are the main method of prophylaxis and current vaccines are
conventionally produced in embryonated hens’ eggs. These
vaccines have been used for more than half a century, and
their quality, safety and efﬁcacy is extensively documented
(reviewed in Ref.7). Most pandemic vaccine development
has focused on the H5 subtype, and although the World
Health Organisation also recognises H7 as a threat
8 there are
only a few candidate H7 vaccine strains available for human
vaccine production.
9–11 During the course of a LPAI H7N1
virus outbreak in domestic poultry in Italy, a HPAI variant
of this virus emerged, which caused widespread disease with
mortality close to 100%.
12 In this study, an HPAI H7N1
virus from this poultry outbreak was chosen as a pandemic
H7 vaccine candidate and an egg grown inactivated inﬂuenza
whole virus vaccine produced. The immunogenicity and the
kinetics of the humoral immune response elicited to this
H7N1 vaccine were investigated in a murine model.
DOI:10.1111/j.1750-2659.2009.00075.x
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Vaccine preparation
An egg grown inactivated H7N1 whole virus vaccine was
prepared as described below. A HPAI A⁄chicken⁄I-
taly⁄13474⁄99 (H7N1) virus, which was lethal to poultry in
an Italian outbreak
12 and in a murine model,
11 was chosen
as a candidate vaccine virus (kindly supplied by Dr L
Campitelli, Italy). Ten day old embryonated hens’ eggs
were inoculated into the allantoic cavity and incubated for
30 hours at 37 C. Allantoic ﬂuid was harvested and clari-
ﬁed by centrifugation. The allantoic ﬂuid was treated with
b- propiolactone (Sigma, UK) to inactivate the virus. A
whole virus vaccine was prepared by concentration of virus
from allantoic ﬂuid by ultracentrifugation followed by
puriﬁcation on a 10–40% sucrose gradient.
13 The total
virus protein was quantiﬁed by the method of Lowry and
adjusted to 10 mg⁄ml and stored in aliquots at )70 C. At
the present time there are no homologous reagents avail-
able for quantifying the amount of haemagglutinin (HA) in
the vaccine by single radial immunodiffusion. A total pro-
tein concentration of 15 lg was used to immunise the mice
in this study, this is approximately 41⁄(3.75 lg HA) lower
than the normal human dose of 15 lg of HA of each of
the three seasonal strains in the current trivalent vaccines.
Mice
Six-week-old female BALB⁄c mice (Taconic M&B A⁄S, Ry,
Denmark) were housed according to the Norwegian Ani-
mal Welfare Act, at a temperature of 21 C, with 12 hour
light⁄dark cycles and food and water ad libitum.
Mice were immunised with 1 or 2 doses, at 3 week inter-
vals, of 15 lg total protein H7N1 whole virus vaccine
intramuscularly into the quadricep muscles of both hind
legs (50 ll per leg). Groups of four animals were sacriﬁced
at a number of days after each dose of vaccine (0, 3 and
5 days after ﬁrst dose and 5, 7 and 21 days after the second
vaccination), the time points of which were established in a
previous study.
14 Mice were exsanguinated by cardiac
puncture and the sera separated and stored at )80 C. The
spleen, femur and tibia bones of the hind limbs were col-
lected and lymphocytes were harvested from each tissue for
use in the enzyme linked immunospot (ELISPOT) assay.
Splenic lymphocytes were separated using lymphoprep
(Axis-Shield PoC AS, Oslo, Norway) and density gradient
centrifugation, whereas lymphocytes were also isolated
from the bone marrow as previously described.
15,16
Haemagglutination inhibition test
Sera were treated to remove non-speciﬁc inhibitors with
receptor destroying enzyme (Denka Seiken, Tokyo, Japan)
overnight at 37 C and then inactivated at 56 C. Haemag-
glutination inhibition (HI) tests were conducted using the
LPAI A⁄turkey⁄Italy⁄3889⁄99 (H7N1) virus, which is anti-
genically similar to the HPAI A⁄chicken⁄Italy⁄13474⁄99
(H7N1), and 0Æ7% turkey red blood or 1% horse red blood
cells.
17 The HI titres are expressed as the reciprocal of the
dilution of serum need to inhibit 50% agglutination. Nega-
tive titres were assigned an arbitrary value of 4 for calcula-
tion of geometric mean titres (GMT).
18
Virus neutralisation assay
Neutralising antibody titres were determined using a previ-
ously described neutralisation assay.
14 Brieﬂy, heat-treated
sera were diluted twofold and incubated in duplicate with
100 TCID50 inﬂuenza A⁄turkey⁄Italy⁄3889⁄99 (H7N1) virus
for 1 hour at room temperature. Residual virus infectivity
was tested on Madin-Darby canine kidney (MDCK) cell
monolayers prepared in 96-well tissue culture plates at room
temperature for 1 hour. After a 72 hour incubation period,
the presence of replicative virus was detected by using an HA
assay with 0Æ7% turkey red blood cells. Wells were scored for
the presence of virus by 100% haemagglutination. Serum
samples were tested in duplicate on at least two occasions
from an initial dilution of 1:20. Sera with titres of 20 or
greater were considered positive. Antibody titres <20 were
assigned an arbitrary value of 10 for calculation purposes.
19
The virus neutralisation titres are expressed as the reciprocal
of the titre required to neutralise 50% of infectious virus, cal-
culated by the method of Reed and Muench.
20
The enzyme linked immunospot (ELISPOT) assay
The ELISPOT assay was used to investigate the class and
IgG subclass of inﬂuenza speciﬁc antibody secreting cell
(ASC) response in the spleen and bone marrow.
15 Brieﬂy,
the ELISPOT plates were coated with 10 lg⁄ml total pro-
tein of A⁄chicken⁄Italy⁄13474⁄99 (H7N1) whole virus vac-
cine diluted in phosphate-buffered saline (PBS) overnight
at 4 C. Lymphocytes (400 000⁄well) from four mice on
each day of sacriﬁce were added in duplicate and incubated
a humidiﬁed CO2 incubator at 37 C overnight. After incu-
bation, the inﬂuenza speciﬁc ASC were detected using
2 lg⁄ml biotinylated class (IgG; 1030-08, IgA; 1040-08,
IgM; 1020-08, Southern Biotechnology, Birmingham, AL,
USA) and IgG subclass (IgG1; 1070-08, IgG2a; 1080-08,
IgG2b; 1090-08, IgG3; 1100-08, Southern Biotechnology)
speciﬁc antibodies and then extravidin peroxidase (Sigma,
St. Louis, MO, USA). The spots were developed and
counted using a dissection microscope. The mean number
of class and IgG subclass speciﬁc ASC per 500 000 lympho-
cytes was calculated for each individual mouse.
ELISA
The class and IgG subclass of inﬂuenza-speciﬁc serum anti-
bodies were detected in an indirect ELISA assay.
14 Brieﬂy,
96-well ELISA plates were coated with 5 lg⁄ml total protein
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diluted in PBS overnight at 4 C. The inﬂuenza speciﬁc anti-
bodies were detected using goat anti-mouse biotinylated
class or IgG subclass speciﬁc antibodies as described under
the ELISPOT assay for 1 hour 45 minutes at room tempera-
ture and subsequent detection with 1⁄1000 dilution of
extravidin peroxidase (Sigma, USA) for 45 minutes. The
background absorbance was subtracted from the sample
absorbance, and the class and IgG subclass antibody con-
centration of inﬂuenza speciﬁc antibody (ng⁄ml) was calcu-
lated for each antibody class and each IgG subclass.
Bead immunoassay
The inﬂuenza speciﬁc IgG antibody response was detected
using a bead-based immunoassay and the Extracellular Pro-
tein Buffer Reagent Kit (LMB0001, Invitrogen, Carlsbad, CA,
USA). One million beads (Bead set 64, 922541; Qiagen, Hil-
den, Germany) were coated according to the manufacturers’
instructions with 20 lg total protein of inactivated whole
A⁄chicken⁄Italy⁄13474⁄99 (H7N1) virus. Mouse sera were
diluted 1⁄100 in sample dilution buffer (PBS-FCS: PBS con-
taining 20% foetal calf sera; 50 ll) and 50 ll of incubation
buffer (PBS-T: PBS with 0Æ5% Tween-20) and incubated with
5000 beads⁄well in a 96 well ﬂat bottom ﬁlter plate
(MSBVN1210, Millipore, Billerica, MA, USA) for 2 hours at
room temperature with agitation (500 rpm). The beads were
then washed twice with PBS-T, and mixed with biotinylated
goat anti-mouse IgG antibody diluted 1:1000 in PBS-T (1030-
08, Southern Biotechnology) for 1 hour. The beads were
washed in PBS-T and then incubated with the streptavidin-
conjugated to the ﬂuorescent protein, R-Phycoerythrin for
30 minutes. After washing twice, the beads were resuspended
in PBS-T (100 ll⁄well) and analysed on a Luminex-100
instrument (Luminex Corp, TX, USA) using StarStation v.2.0
software (Applied Cytometry, Shefﬁeld, UK). The relative
quantities of IgG antibodies are presented as a mean ﬂuores-
cent intensity (MFI) after subtraction of the background MFI.
Statistical analyses
Statistical analyses were performed using Prism 5 for Mac
OSX (Graphpad Software Inc. La Jolla, USA). The HI,
ELISA and Luminescent antibody results were analysed
using the unpaired Student’s t-test by comparing groups
of mice to the preceding day of sacriﬁce. For all assays,
P-values £ 0Æ05 were considered signiﬁcant.
Results
The kinetics of the humoral antibody secreting cell and
serum antibody responses after H7N1 vaccination were
investigated in the BALB⁄c mice using a number of differ-
ent immunological assays.
Inﬂuenza speciﬁc antibody secreting cell response
The ELISPOT assay was used to enumerate the inﬂuenza
speciﬁc antibody secreting cell (IS-ASC) response elicited
Table 1. The IS-ASC response in the spleen and bone marrow after inﬂuenza H7N1 vaccination of BALB⁄c mice
Organ
Antibody
class ⁄IgG
subclass
Days post ﬁrst vaccination Days post second vaccination
05 73 5 2 1
Spleen IgM 4Æ4±0 Æ62 8 Æ9±1 0 Æ89 Æ1±6 Æ51 4 Æ1±6 Æ09 Æ1±2 Æ48 Æ2±2 Æ5
IgA < < < 9Æ2±3 Æ61 5 Æ7±4 Æ20 Æ3±0 Æ3
IgG 0Æ6±0 Æ60 Æ2±0 Æ2< 3 3 Æ5±1 0 Æ93 2 Æ4±6 Æ23 Æ0±1 Æ4
IgG1 < < < 5Æ7±3 Æ23 Æ8±2 Æ01 Æ0±0 Æ6
IgG2a < 0Æ2±0 Æ2< 3 0 Æ9±8 Æ11 9 Æ7±3 Æ70 Æ4±0 Æ2
IgG2b < 1Æ1±0 Æ5< 8 Æ3±3 Æ27 Æ0±1 Æ20 Æ5±0 Æ5
IgG3 < < < 5Æ0±3 Æ80 Æ5±0 Æ50 Æ5±0 Æ3
Bone
marrow
IgM 0Æ8±0 Æ64 Æ4±1 Æ43 Æ9±1 Æ43 Æ9±1 Æ47 Æ4±5 Æ71 Æ9±0 Æ8
IgA < < < 0Æ6±0 3 Æ8±1 Æ4<
IgG < < < 1Æ4±0 Æ47 Æ8±2 Æ51 Æ9±0 Æ6
IgG1 < < < 0Æ3±0 Æ30 Æ3±0 Æ21 Æ1±0 Æ5
IgG2a < < < 3Æ1±1 Æ21 Æ6±0 Æ40 Æ2±0 Æ2
IgG2b < < < 1Æ0±0 Æ40 Æ8±0 Æ40 Æ2±0 Æ2
IgG3 <<<< 0 Æ2±0 Æ20 Æ5±0 Æ5
<no speciﬁc IS-ASC detected per 500 000 lymphocytes.
BALB⁄c mice were immunised with one or two doses of whole virus vaccine (15 lg total protein). Groups of four mice were sacriﬁced after vacci-
nation or control unimmunised mice (0) and the antibody secreting cell response measured by ELISPOT assay. The mean number of inﬂuenza
H7N1 speciﬁc antibody secreting cells per 500 000 lymphocytes ± standard error of the mean (SEM).
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the ﬁrst and second vaccination.
After the ﬁrst dose, only splenic IgM IS-ASC were
detected (range 0–60 IS-ASC per 500 000 lymphocytes), with
the exception of one mouse that had very low numbers of
IgG ASC (Table 1). Higher numbers of IS-ASC were
detected 5 days after the ﬁrst vaccination than at day 7. After
the second immunisation, low number of IS-ASC secreting
all antibody classes (IgG, IgA and IgM) were detected,
although IgG IS-ASC dominated the splenic response at days
3 and 5 (range 8–60 IS-ASC per 500 000 lymphocytes). This
IgG IS-ASC response consisted mainly of the IgG2a subclass
and had the following distribution; IgG2a > IgG2b > IgG1
> IgG3. Higher numbers of splenic IS-ASC were detected at
3 than 5 days after the second vaccination.
In the bone marrow, only very low numbers of IS-ASC
were detected (range 0–24 IS-ASC per 500 000 lympho-
cytes). The response consisted of IgM after the ﬁrst dose of
vaccine, whereas all antibody classes (IgM, IgA and IgG)
were detected after the second dose. The highest numbers
of IS-ASC were elicited 5 days after the second vaccination
with higher number of IgG ASC mainly secreting the IgG2a
subclass. The number of speciﬁc IS-ASC in the bone mar-
row decreased by 21 days after the second immunisation.
Inﬂuenza speciﬁc serum antibody responses
HI and neutralising serum antibody response
The HI assay is conventionally used with turkey erythro-
cytes, but has proved to be less sensitive for detecting anti-
bodies to avian H5 inﬂuenza viruses and recently the use of
horse erythrocytes in the HI test has been found to greatly
increase the sensitivity of the assay.
21 Thus, in this study the
HI assays were conducted with both turkey and horse
erythrocytes. We found that only one mouse had detectable
HI antibody using horse erythrocytes at 5 days after the ﬁrst
immunisation, but by day 7 all animals had low HI titres. In
contrast, no HI antibody was detected using turkey erythro-
cytes after the ﬁrst vaccination. The second dose of vaccine
signiﬁcantly boosted the HI titres (P <0 Æ05 t-test) with anti-
body titres detected by horse erythrocytes increasing up to
day 5 and then remaining stable until day 21 (GMT = 211).
In contrast, the HI titres measured using turkey blood cells
were much lower and continued to increase up to 21 days
post the second dose (GMT = 32) (Figure 1A).
The ability of the serum antibodies to neutralise live
virus was measured. No neutralising antibody was detected
after the ﬁrst vaccination. Neutralising antibody was found
in one mouse at 3 days after the second immunisation
(mean titre = 78) and all mice tested at 5 and 21 days
(mean titre from 34 to 160) (Figure 1B).
IgG response measured by the bead immunoassay
We have developed a bead-based immunoassay to detect
the inﬂuenza speciﬁc IgG antibody response after vaccina-
tion, which uses low concentrations of virus and small
volumes of sera. Only very low levels of inﬂuenza speciﬁc
IgG antibodies were detected at 5 and 7 days post the ﬁrst
immunisation, MFI 14 and 4 on each day respectively (Fig-
ure 2A). The antibody titres increased signiﬁcantly
(P <0 Æ05) after the second dose of vaccine and continued
to increase up to day 21 (MFI 131).
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Figure 1. The antibody response induced after vaccination. BALB⁄c mice were immunised with one or two doses of whole virus vaccine 15 lg total
protein. Groups of four mice were sacriﬁced after vaccination and the serum antibody response analysed by HI and neutralisation assay. (A) The
haemagglutination inhibition (HI) antibody response induced after vaccination. The HI titres were measured in an HI assay using turkey (ﬁlled symbols)
or horse erythrocytes (open symbols). The data are presented as the geometric mean titre ± 95% conﬁdence interval. There was a signiﬁcant
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day after each dose of vaccine.
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The ELISA was used to measure the class and IgG subclass
of inﬂuenza speciﬁc antibody responses after vaccination
(Figure 2B, C). Low concentrations of speciﬁc antibody,
particularly IgM, were detected 5 days after the ﬁrst vacci-
nation, however the concentration of IgG and IgM
increased by day 7. The IgG antibody response was signiﬁ-
cantly (P <0 Æ05) boosted in animals immunised twice,
with the highest concentrations detected at day 21. In con-
trast, the IgM concentration remained constant and then
decreased by day 21. Low levels of IgG2a were elicited after
the ﬁrst dose, and the second vaccination signiﬁcantly
boosted this response. IgG1 was only detected after the sec-
ond vaccination and the concentration of this subclass
increased up to day 21, but always remained markedly
lower than of IgG2a. The IgG subclass response had the
following distribution; IgG2a > IgG2b > IgG1 > IgG3.
Discussion
The inﬂuenza H7 subtype has caused zoonoses in Europe
and North America, resulting in asymptomatic illness, con-
junctivitis and one known death.
3,4,6 The avian inﬂuenza
H7 viruses can be subdivided into two geographic and phy-
logenetic lineages, the Eurasian and North American.
22 For
sustained human-to-human transmission to occur avian
viruses must adapt to humans by changing the HA recep-
tor speciﬁcity for a2,6- rather than a2,3-linked sialic acid
(SA) receptors.
23 Recently, the North American H7 viruses
were shown to have acquired binding to the human a2,6
SA receptor,
24 although for efﬁcient human-to-human
spread further adaptations are probably required in the
viral genes to allow further adaptation to the mammalian
cell.
25 H7 viruses thus represent a potential pandemic
threat and there is therefore a need to investigate candidate
H7 vaccines in pre-clinical animal models and clinical tri-
als. The Eurasian strains of H7 have been found to elicit
more cross reactive antibody responses than the North
American viruses.
26 Thus in this pilot study, we have inves-
tigated the humoral immune response in a mouse model
to an inactivated whole virus vaccine produced from an
HPAI Eurasian H7N1 virus.
Candidate pandemic H5 and H9 vaccines have been
found to be poorly immunogenic in man
27–30 and two
doses of vaccine are required to produce protective levels
of serum antibody. Vaccine candidates containing H2, H5
and H9 have undergone clinical trials and have after two
doses fulﬁlled the conventional licensing criteria
30–32
deﬁned by the Committee for Medicinal Products for
Human Use (CHMP) for seasonal inﬂuenza vaccines.
33
Most inactivated inﬂuenza vaccines are produced in three
formulations; whole virus, split virus or subunit vaccines.
Whole virus vaccine is more immunogenic in naı ¨ve indi-
viduals as it elicits systemic antibodies, as well as primes
for a cytotoxic lymphocyte response.
34,35 In this study, we
detected low HI antibody titres after the ﬁrst immunisa-
tion, but the HI and neutralising titres increased rapidly
after the second dose. We have previously observed that
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Figure 2. The antibody response induced after vaccination. BALB⁄c mice were immunised with one or two doses of whole virus vaccine (15 lg total
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earlier and stronger humoral immune response in naı ¨ve
animals,
14 thus it may also induce earlier and better protec-
tion against infection and its associated medical complica-
tions in man.
Once antigenically activated, B cells differentiate into
memory B cells and plasmablasts, which secrete antibody
before becoming fully differentiated into plasma cells.
36 We
found that this H7N1 vaccine elicited an ASC IgM
response after the ﬁrst vaccination, whereas all three classes
of antibody were secreted by ASC after the second dose.
Whole H7N1 vaccine elicited an IgA ASC response after
the second dose of vaccine, although lower than IgG and
IgM, and may point to the inherent ability of whole virus
vaccine to elicit an IgA response. Locally produced IgA is
important in providing the ﬁrst line of defence against
inﬂuenza virus, and furthermore reacts with antigenically
drifted inﬂuenza variant (reviewed in Ref.37). After activa-
tion by antigen in the secondary lymphoid organs, B cells
differentiate into short-lived or long-lived ASC and the lat-
ter home to the bone marrow.
38 The number of IgG ASC
in the bone marrow decreased 3 weeks after the second
vaccination with H7N1 vaccine, which contrasts with the
ﬁnding of stable bone marrow ASC numbers after immuni-
sation with a seasonal strain
14 suggesting a lower induc-
tion of a memory B-cell response. This A⁄chicken⁄Italy⁄
13474⁄99 (H7N1) virus may have a particularly low intrin-
sic immunogenicity as we have observed lower antibody
response upon infection of ferrets.
11 These ﬁndings require
further studies as the induction of a good memory B cell
response are essential characteristic for an effective vaccine.
Haemagglutination inhibitory antibodies are considered
surrogate correlates of protection and an HI titre of ‡40 is
considered to indicate 50% protection in humans to sea-
sonal inﬂuenza strains. The conventional HI assay using
turkey red blood cells is relatively insensitive for detecting
antibody responses to avian H5 viruses.
19,27 In this study,
the use of horse erythrocytes increased the sensitivity of
detection of serum H7 HI titres, and two doses of H7N1
vaccine was seen to elicit HI antibody titres considered to
be protective. This is in agreement with the ﬁndings of
others with an avian H7 virus.
39 However, despite the
increased sensitivity of the assay, the HI titres were much
lower than those observed in other murine studies with
H3N2 whole virus vaccine
14,40 and this may reﬂect lack of
optimised assays for detecting antibody responses to avian
H7 viruses. Other studies have found that the formulation
of the vaccine with immune stimulating complex adjuvant
(ISCOM) or aluminium adjuvants improved the immuno-
genicity of candidate H7 vaccines.
9,10,41 Although, a recent
study in man of a pandemic H5N1 vaccine found that
whole virus vaccine induced higher antibody titres when
administered alone than with alum adjuvant.
31
The IgG subclass proﬁle elicited after vaccination can
provide important information on the quality of the
immune response. The IgG2a antibody response is a mar-
ker of a Th1 cellular response and IgG1 as an indicator of
Th2 humoral response.
35 In this study we observed a domi-
nance of IgG2a antibody after the ﬁrst vaccination indicat-
ing a dominant Th1 response, whereas the concentration of
IgG1 increased after the second dose representing a mixed
Th1⁄Th2 proﬁle. Similar results have been observed after
seasonal whole virus vaccine and the IgG2a antibody is
associated with a strong IFN-c response after one dose and
a more mixed cytokine response including the Th2 cyto-
kine IL-4, IL-6 and IL-10 after the second immunisa-
tion.
14,40 We have found a mixed Th1⁄Th2 proﬁle in
mice infected with this HPAI H7N1
42 suggesting that the
response observed after the second immunisation was more
similar to that observed after natural infection. Also, the
ratio of IgG2a and IgG1 serum antibodies and IS-ASC in
spleen and bone marrow differed not only after each vac-
cine dose, but also at the various time points following the
second dose. This highlights that the time points selected
for analysing the IgG2a⁄IgG1 antibody ratios are impor-
tant, as the overall pattern shows a change from a Th1 to a
Th2 proﬁle.
There is only one published human clinical trial of wild-
type HPAI H5 vaccine
31 as most vaccine manufactures do
not have high containment vaccine production facilities.
An H7N1 vaccine strain containing an attenuated HA and
the neuraminidase derived from this H7N1 strain has been
produced by reverse genetics and a cell-based inactivated
split virion vaccine was manufactured and has entered
phase I clinical trial.
11,43 In other studies, we have found
that a cell-based split virion vaccine based on this highly
pathogenic H7N1 strain induced only low serum antibody
titres consisting almost entirely of IgG1, but protected from
disease and death in a murine challenge model.
42 In con-
trast, this H7N1 whole virus vaccine induced a strong Th1
immune response as measured by IgG2a subclass after one
dose of vaccine and a more mixed Th1⁄Th2 response with
HI and neutralising antibodies after the second dose.
Recently, others have found that the protective efﬁcacy of
pandemic candidate H5 vaccines have shown that correlates
of resistance to serious illness and death to avian viruses
may not be solely reﬂected by levels of circulating serum
antibodies.
44–47 Thus, the methodology used in this study
may aid in future studies deﬁning immunological correlates
to pandemic candidate vaccines.
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